http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022031690-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8000416aa10323198c9cd857c22c766 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate | 2019-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c78a73196ea63812673b9f6931af709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25070c947f47595a5136564a0e39bc73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f0a80fd618e052b47fe594ca3eee833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18195c6b46991cc7837bc7e36596ee16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_699b5c0057e416bd549cad74e8e6f8ff |
| publicationDate | 2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022031690-A1 |
| titleOfInvention | Anti-neurodegenerative disease agent |
| abstract | The present invention addresses the problem of providing an orally-administrable anti-neurodegenerative disease agent having an action of accelerating neurocyte growth and an action of promoting neurite-outgrowth, and having excellent transfer properties to central nervous tissues. The problem is solved by providing an anti-neurodegenerative disease agent containing a compound represented by General formula 4 as an active ingredient, and having an action of accelerating neurocyte growth, an action of promoting neurite-outgrowth, and an action of scavenging reactive oxygen species. In General formula 4, R10 and R11 represent the same or different alkyl group having 2-8 carbon atoms, and the alkyl group may be either a straight chain or a branched chain. n represents an integer of 0 or 1, and X4− represents a suitable counter anion that is pharmaceutically acceptable. |
| priorityDate | 2018-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 339.